NYSE:KDMNKadmon Stock Price, Forecast & News

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KDMN shares have increased by 28.2% and is now trading at $4.46. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Kadmon.

Kadmon is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Kadmon.

Kadmon Holdings Inc (NYSE:KDMN) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.14) by $0.05. The company earned $6.74 million during the quarter, compared to analysts' expectations of $0.38 million. Kadmon had a negative net margin of 813.33% and a negative return on equity of 142.79%. View Kadmon's earnings history.

5 Wall Street analysts have issued 12 month price targets for Kadmon's stock. Their forecasts range from $7.00 to $25.00. On average, they anticipate Kadmon's stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 169.1% from the stock's current price. View analysts' price targets for Kadmon.

Headlines about KDMN stock have trended somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kadmon earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news aboutKadmon.

Some companies that are related to Kadmon include Uniqure (QURE), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Amarin (AMRN), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Intercept Pharmaceuticals (ICPT), Karuna Therapeutics (KRTX), Turning Point Therapeutics (TPTX), Ra Pharmaceuticals (RARX), Principia Biopharma (PRNB), TG Therapeutics (TGTX) and Prestige Consumer Healthcare (PBH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Kadmon investors own include Iovance Biotherapeutics (IOVA), Applied Materials (AMAT), Biocept (BIOC), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Viking Therapeutics (VKTX), Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and Global Blood Therapeutics (GBT).

(KDMN) raised $101 million in an initial public offering on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Kadmon's stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.82%), Vivo Capital LLC (7.84%), BlackRock Inc. (7.53%), State Street Corp (2.33%), Geode Capital Management LLC (1.41%) and Invesco Ltd. (1.12%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc. View institutional ownership trends for Kadmon.

KDMN stock was sold by a variety of institutional investors in the last quarter, including Sofinnova Investments Inc., Invesco Ltd., Nuveen Asset Management LLC, Ghost Tree Capital LLC, Two Sigma Investments LP, Soleus Capital Management L.P., Telemetry Investments L.L.C., and Acadian Asset Management LLC. View insider buying and selling activity for Kadmon.

KDMN stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, Perceptive Advisors LLC, Healthcare of Ontario Pension Plan Trust Fund, and Two Sigma Advisers LP. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc. View insider buying and selling activity for Kadmon.

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KDMN stock can currently be purchased for approximately $4.46.

Kadmon has a market capitalization of $713.73 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe.

The official website for Kadmon is www.kadmon.com.

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]